Latest & greatest articles for citalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on citalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on citalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for citalopram

1. Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS)

Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS) Background and Purpose- Recent studies indicate a possible beneficial effect on neuroregeneration and vascular protection of selective serotonin reuptake inhibitors after stroke. We conducted a national multicentre study to explore these effects. Methods- The TALOS study (The Efficacy of Citalopram Treatment in Acute Stroke) is a Danish placebo-controlled, randomized, double-blind study of citalopram (...) during the first 6 months. Results- We enrolled 642 patients randomized to either citalopram (n=319) or placebo (n=323). Median National Institutes of Health Stroke Scale was 5.3 (range, 0-27) versus 4.8 (range, 0-28) at admission. Improvement in functional recovery from 1 to 6 months occurred in 160 (50%) patients on citalopram and 136 (42%) on placebo (odds ratio, 1.27; 95% CI, 0.92-1.74; P=0.057). When dropouts before 31 days were excluded (n=90), the analysis population showed an odds ratio

Full Text available with Trip Pro

2019 EvidenceUpdates

2. Citalopram

Citalopram Top results for citalopram - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for citalopram The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial The present study aimed to assess the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities.A randomized double-blind placebo-controlled clinical trial was conducted between January 2015 and January 2016.The neurology department of a university-affiliated urban (...) hospital in Tehran, Iran.Ninety adult patients with acute ischemic stroke, hemiplegia, or hemiparesis and a Fugl-Meyer Motor Scale score of below 55 were included.Participants were randomly allocated to one of three groups: Group A received 20 mg PO of fluoxetine daily, Group B received 20 mg PO of citalopram daily, and Group C received a placebo PO The duration of the therapy was 90 days. In addition to the medications, all of the participants received physiotherapy.Functional status at 90 days, which

2018 EvidenceUpdates

4. Citalopram and escitalopram: opt for other SSRI antidepressants

Citalopram and escitalopram: opt for other SSRI antidepressants Prescrire IN ENGLISH - Spotlight ''Citalopram and escitalopram: opt for other SSRI antidepressants'', 1 September 2016 {1} {1} {1} | | > > > Citalopram and escitalopram: opt for other SSRI antidepressants Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Citalopram and escitalopram: opt (...) for other SSRI antidepressants As of early 2016, studies point to the same overall conclusion: that citalopram and its derivative escitalopram expose patients to a higher risk of cardiac disorders than other SSRI antidepressants. Citalopram and escitalopram are selective serotonin reuptake inhibitors (SSRI). These two drugs are no more effective than other SSRI antidepressants, and their adverse effects profile is also very similar. In 2011 and 2012, the Food and Drug Administration (FDA) issued

2016 Prescrire

5. Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use Possible illicit drug use should be considered when prescribing medicines that have (...) the potential to interact adversely. Published 18 July 2016 From: Therapeutic area: Contents Suspected drug interaction between citalopram and cocaine We received a that raised concerns about a suspected drug interaction between citalopram and cocaine after the death of a man due to subarachnoid haemorrhage. The case was discussed by the UK Commission on Human Medicine’s Pharmacovigilance Expert Advisory Group. There are plausible mechanisms for an interaction between cocaine and citalopram that could lead

2016 MHRA Drug Safety Update

6. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer`s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial (PubMed)

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer`s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial Pharmacological treatments for agitation and aggression in patients with Alzheimer's disease have shown limited efficacy. The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed.In this double-blind parallel-group (...) multicenter trial of 186 patients with Alzheimer's disease and clinically significant agitation, participants were randomly assigned to receive citalopram or placebo for 9 weeks, with the dosage titrated to 30 mg/day over the first 3 weeks. Five planned potential predictors of treatment outcome were assessed, along with six additional predictors. The authors then used a two-stage multivariate method to select the most likely predictors; grouped participants into 10 subgroups by their index scores

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

7. Pharmacological interventions: Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram

Pharmacological interventions: Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) with citalopram Article Text Further commentaries Electronic pages Pharmacological interventions Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram Nathan Herrmann Statistics from Altmetric.com ABSTRACT FROM: Schneider LS, Frangakis, C, Drye LT, et al . Heterogeneity of treatment response to citalopram for patients with Alzheimer's disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry 2016;173:465–72

2016 Evidence-Based Mental Health

8. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. (PubMed)

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety (...) , cognitive safety, and tolerability.The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013.Participants (n = 186) were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage

2014 JAMA Controlled trial quality: predicted high

9. Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram decreases agitation in the context

2014 Evidence-Based Medicine (Requires free registration)

10. Citalopram

Citalopram USE OF CITALOPRAM IN PREGNANCY 0344 892 0909 USE OF CITALOPRAM IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Citalopram is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression and panic disorder. Two studies have suggested that the risk of any major malformation is increased following maternal citalopram use in pregnancy, and a small number of studies have identified statistically significant increased risks of specific congenital malformations, including cardiac malformation. However, the majority of primary data studies and meta-analyses have failed to demonstrate a statistically significant increase in the risk of overall malformation rate

2014 UK Teratology Information Service

11. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. (PubMed)

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety (...) , cognitive safety, and tolerability.The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013.Participants (n = 186) were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage

Full Text available with Trip Pro

2014 JAMA Controlled trial quality: predicted high

12. Citalopram effective for major depression

Citalopram effective for major depression Citalopram effective for major depression | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Citalopram effective for major depression Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

13. Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs

Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference

2013 Evidence-Based Mental Health

14. Efficacy of escitalopram compared to citalopram: a meta-analysis

Efficacy of escitalopram compared to citalopram: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

15. Citalopram and escitalopram: QT interval prolongation

Citalopram and escitalopram: QT interval prolongation Citalopram and escitalopram: QT interval prolongation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Citalopram and escitalopram: QT interval prolongation New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Published 11 December 2014 From: Therapeutic area: Contents Article date: December 2011 Citalopram, a racemic mixture of R and S citalopram, is a selective serotonin (...) reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, panic disorder, and obsessive compulsive disorder. Escitalopram is the S enantiomer of citalopram indicated for major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder, and obsessive compulsive disorder. New data for QT prolongation with citalopram and escitalopram The potential for citalopram and escitalopram to cause QT interval

2011 MHRA Drug Safety Update

16. Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Apler A CRD summary The review concluded that citalopram had a statistically significant advantage over placebo (...) with respect to symptom improvement and response rates in adults with major depressive disorder, but its role in symptom remission was less clear. The sub-optimal quality of the trials and small evidence base limit the reliability of the author’s results. Authors' objectives To assess the effectiveness of citalopram for major depressive disorder in adults. Searching Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, PsycINFO and MEDLINE were searched to February 2011. Search terms were

Full Text available with Trip Pro

2011 DARE.

17. Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy

Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy Article Text Aetiology Increased risk

2010 Evidence-Based Mental Health

18. Citalopram not effective for repetitive behaviour in autistic spectrum disorders

Citalopram not effective for repetitive behaviour in autistic spectrum disorders Citalopram not effective for repetitive behaviour in autistic spectrum disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram not effective for repetitive behaviour in autistic spectrum disorders Article Text Therapeutics Citalopram not effective for repetitive behaviour in autistic spectrum disorders Statistics from Altmetric.com Question

2010 Evidence-Based Mental Health

19. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Statistics from Altmetric.com Question Question Is the antidepressant venlafaxine associated with an increased risk of sudden cardiac death compared with other antidepressants? People The cohort consisted of 207 384 new users of venlafaxine, fluoxetine, citalopram or dosulepin

2010 Evidence-Based Mental Health

20. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials

Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Trkulja V CRD summary This review compared (...) the efficacy of equimolar doses of escitalopram and citalopram in patients with major depressive disorder. The author concluded that claims to the clinically relevant superiority of escitalopram over citalopram in the short-to-medium term were not supported. This conclusion reflected the variable evidence presented, but its reliability is unclear due to potential methodological shortcomings in the review process. Authors' objectives To compare the efficacy of equimolar escitalopram and citalopram

Full Text available with Trip Pro

2010 DARE.